CLASS II Device recall · Reported 24 Apr 2019 · FDA Enforcement Report

Bilirubin Total Gen.3, Cat recalled by Roche Diagnostics

Roche Diagnostics is recalling Bilirubin Total Gen.3, Cat, distributed nationwide in the US. The recall was initiated on 17 Dec 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesn/a
Quantity recalled5292 analytical units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1145-2019
FDA event ID
81859
Recalling firm
Roche Diagnostics, Indianapolis, IN
Classification
Class II
Status
Terminated
Recall initiated
17 Dec 2018
FDA classified
13 Apr 2019
Reported
24 Apr 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

17 Dec 2018Recall initiated by company
13 Apr 2019Classified by FDA+117 days
24 Apr 2019Published in enforcement report+11 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

New endogenous interference claims have been established for the following assays used on the cobas c 311 analyzer and the cobas c 501, 502, 701, 702, and Modular Analytics P/D modules which may have potential medical risk. ***Update: Cobas c111 and COBAS INTEGRA 400 plus analyzers are also impacted for BILT3 and LACT2 assays***

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Bilirubin Total Gen.3, Cat. Nos. 05795397190, 05795419190, 05795320160, 05795338160, 05795346160 ***added as of 5/10/19***05795397190, 05795648190 Product Usage: In vitro test for the quantitative determination of total bilirubin in serum and plasma of adults and neonates on Roche/Hitachi cobas c systems.

Where it was distributed

US Nationwide distribution.

Nationwide

Questions about this recall

Is Bilirubin Total Gen.3, Cat recalled?

Yes. Roche Diagnostics recalled Bilirubin Total Gen.3, Cat on 17 Dec 2018. The recall is Class II and its status is Terminated. Recall number Z-1145-2019.

Why was it recalled?

New endogenous interference claims have been established for the following assays used on the cobas c 311 analyzer and the cobas c 501, 502, 701, 702, and Modular Analytics P/D modules which may have potential medical risk. ***Update: Cobas c111 and COBAS INTEGRA 400 plus analyzers are also impacted for BILT3 and LACT2 assays***

Which lots are affected?

n/a

Where was it sold?

US Nationwide distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Roche Diagnostics

All 39

Other Test Kits & Diagnostics recalls

All 2,656